Department of Oncology & Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, Ontario, Canada.
Expert Rev Pharmacoecon Outcomes Res. 2011 Apr;11(2):151-61. doi: 10.1586/erp.11.11.
The Inventory of Cancer Guidelines (ICG) was designed to mitigate challenges associated with inconsistencies in the quality of cancer guidelines, keeping guidelines current and the duplication of effort in guideline development. The ICG is a searchable database of quality-appraised guidelines in cancer control that also includes designations of guidelines in progress, those in need of an update and those currently being updated. From a clinical perspective, the majority of the completed guidelines target breast, lung, colorectal and prostate cancers, and focus on the treatment stage of the cancer continuum. There is considerable variability in guideline quality both within and across guideline developers, as measured by the Appraisal of Guidelines for Research and Evaluation II. Quality domains of applicability and editorial independence are the guideline quality domains that score the poorest. While the ability to inform on the status of cancer control guidelines is important, the real potential of the ICG is in its ability to leverage positive change in the guideline enterprise. Pilot projects are underway to use data from the ICG to tailor audit and feedback interventions for guideline developers and to pursue collaborative updating and guideline adaptation initiatives, using the ICG as the platform from which these partnerships can evolve.
《癌症指南目录》（ICG）旨在减轻癌症指南质量不一致、保持指南最新和指南开发工作重复等方面的挑战。ICG 是一个可搜索的癌症控制质量评估指南数据库，其中还包括正在进行中的指南、需要更新的指南和正在更新的指南的指定。从临床角度来看，大多数已完成的指南针对乳腺癌、肺癌、结直肠癌和前列腺癌，并侧重于癌症连续体的治疗阶段。在指南制定者内部和之间，指南质量存在相当大的差异，这是由《研究和评估指南的评估》II 衡量的。适用性和编辑独立性是指南质量领域得分最低的。虽然了解癌症控制指南的现状很重要，但 ICG 的真正潜力在于其能够在指南企业中实现积极的变革。正在进行试点项目，以利用 ICG 中的数据为指南制定者量身定制审核和反馈干预措施，并寻求合作更新和指南适应倡议，使用 ICG 作为这些伙伴关系可以发展的平台。
